9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

ConditionOvarian Neoplasms|Colorectal Neoplasms|Melanoma|Small Cell Lung Cancer|LiposarcomaEstimated Enrollment: 149Age Group: 19 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: 04-109Study First Received: August 18, 2005Last Updated: July 23, 2014Estimated Primary Completion Date: July 2014Primary Outcome Measures:apoptotic responseSponsors and Collaborators:Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00132704...

Continue reading

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

ConditionCancerEstimated Enrollment: 75Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 010124|01-C-0124|NCI-2792|CDR0000068615Study First Received: July 11, 2001Last Updated: March 14, 2012Estimated Primary Completion Date: April 2008Primary Outcome Measures:Dose-limiting toxicities and maximum tolerated dose|Pharmacology and pharmacokinetics|Acetylation of histones in peripheral blood|Tumor response by CT scan every 12 weeksSponsors and Collaborators:National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00020579...

Continue reading

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

ConditionAdvanced Solid TumorsEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: OSI-930-103Study First Received: December 26, 2007Last Updated: September 26, 2011Estimated Primary Completion Date: April 2010Primary Outcome Measures:Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationshipsSponsors and Collaborators:Astellas Pharma Inc|OSI PharmaceuticalsResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00603356...

Continue reading

Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy

ConditionPleural Effusion|Pleural DiseasesEstimated Enrollment: 124Age Group: 18 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Primary Purpose: DiagnosticStudy ID Numbers: 2007.11.008Study First Received: July 21, 2008Last Updated: July 22, 2008Estimated Primary Completion Date: June 2008Primary Outcome Measures:Efficacy and safety of both thoracoscopy and CT-guided pleural needle biopsy for diagnosis of pleural diseases|Determine the efficacy of pleural needle biopsy and thoracoscopy in relation to CT findings.Sponsors and Collaborators:Eskisehir Osmangazi UniversityResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00720954...

Continue reading

Rapamycin With Grapefruit Juice for Advanced Malignancies

ConditionTumors|Neoplasm MetastasisEstimated Enrollment: 41Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 14435BStudy First Received: September 11, 2006Last Updated: January 16, 2014Estimated Primary Completion Date: May 2009Primary Outcome Measures:Pharmacokinetic interactionSponsors and Collaborators:University of ChicagoResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00375245...

Continue reading

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

ConditionLife Threatening DiseasesEstimated Enrollment: 185Age Group: 15 Years to 70 Years   (Child, Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CSTI571B2225Study First Received: September 9, 2005Last Updated: November 16, 2016Estimated Primary Completion Date: January 2007Primary Outcome Measures:To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases|To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease|To assess the safety and tolerability of Imatinib mesylate|To evaluate the pharmacokinetic profile of Imatinib mesylate|To assess,...

Continue reading

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

ConditionTumorEstimated Enrollment: 35Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: PXD101-CLN-4Study First Received: December 18, 2006Last Updated: July 7, 2015Estimated Primary Completion Date: March 2008Primary Outcome Measures:to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU|to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumorsSponsors and Collaborators:OnxeoResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00413322...

Continue reading

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

ConditionSolid Tumor|LymphomaEstimated Enrollment: 121Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: PXD101-CLN-9Study First Received: December 18, 2006Last Updated: July 7, 2015Estimated Primary Completion Date: August 2011Primary Outcome Measures:Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphomaSponsors and Collaborators:Onxeo|Spectrum Pharmaceuticals, IncResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00413075...

Continue reading

E-MOSAIC Electronic Tool to Monitor Symptoms

ConditionCancerEstimated Enrollment: 264Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation:Study ID Numbers: SAKK 95/06|EU-20711Study First Received: May 23, 2007Last Updated: October 8, 2015Estimated Primary Completion Date: January 2012Primary Outcome Measures:Determine the effect of an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC) and a Longitudinal Monitoring Sheet (LoMoS) on global quality of life (G-QOL)|Determine if this tool affects communication between these patients and their treating physicians.|Determine if this tool affects the symptoms and syndromes reported by these patients|Determine if this tool impacts symptom management performanceSponsors and Collaborators:Swiss Group for...

Continue reading

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

ConditionCancerEstimated Enrollment: nullAge Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000270801|MSKCC-02080|NCI-1617Study First Received: March 6, 2003Last Updated: April 23, 2011Estimated Primary Completion Date: nullPrimary Outcome Measures:Sponsors and Collaborators:Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00055705...

Continue reading